^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EphA3 inhibitor

    Related drugs:
    4ms
    EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. (PubMed, J Immunother Cancer)
    Building on the proven safety profile of EphA3 antibodies in clinical settings, our study provides compelling preclinical evidence supporting the efficacy of EphA3-targeted CAR T cells against high-grade gliomas. These findings underscore the potential for transitioning this innovative therapy into clinical trials, aiming to revolutionize the treatment landscape for patients afflicted with these formidable brain cancers.
    Journal • CAR T-Cell Therapy
    |
    EPHA3 (EPH receptor A3)
    4ms
    EphA3 CAR T cells are effective against glioblastoma in preclinical models. (PubMed, J Immunother Cancer)
    This study provides compelling evidence supporting the therapeutic potential of EphA3 CAR T-cell therapy against glioblastoma by targeting EphA3 associated with brain cancer stem cells and the tumor vasculature. The ability to target patient-derived glioblastoma underscores the translational significance of this EphA3 CAR T-cell therapy in the pursuit of effective and targeted glioblastoma treatment strategies.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    EPHA3 (EPH receptor A3)
    11ms
    Contrasting Effects of Cancer-Associated Mutations in EphA3 and EphB2 Kinases. (PubMed, Biochemistry)
    The reciprocal effects of EphB2 and EphA3 on ERK phosphorylation in HEK293T cells were also evident in Ras-GTP loading. Thus, consistent with the dual roles of Eph receptors as tumor promoters and tumor suppressors, somatic mutations have the potential to increase or decrease Eph function, resulting in changes in the downstream signaling transduction.
    Journal
    |
    EPHA3 (EPH receptor A3) • EPHB2 (EPH Receptor B2)
    |
    EPHA3 mutation
    1year
    EphA3 CART: Dual Targeting of Glioblastoma and Tumor Microenvironment (SNO 2023)
    EphA3 CART is able to overcome and ameliorate the effect of a major component of the tumor microenvironment (TME), M2 macrophages. EphA3 CART appears effective in flank and orthotopic mouse models of GBM.
    EPHA3 (EPH receptor A3)
    1year
    EphA3 CART: Dual Targeting of Glioblastoma and Tumor Microenvironment (SNO 2023)
    EphA3 CART is able to overcome and ameliorate the effect of a major component of the tumor microenvironment (TME), M2 macrophages. EphA3 CART appears effective in flank and orthotopic mouse models of GBM.
    EPHA3 (EPH receptor A3)
    1year
    Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression. (PubMed, Cancers (Basel))
    Single cell RNA sequencing analysis of multiple human tumour types confirmed EphA3 expression in CAFs, including in breast cancer, where EphA3 was particularly prominent in perivascular- and myofibroblast-like CAFs. Our results thus indicate expression of the cell guidance receptor EphA3 in distinct CAF subpopulations is important in supporting tumour angiogenesis and tumour growth, highlighting its potential as a therapeutic target.
    Journal • Stroma
    |
    EPHA3 (EPH receptor A3)
    over1year
    The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. (PubMed, J Exp Clin Cancer Res)
    Our data demonstrate that RAGE up-regulation leads to migratory ability in ER-positive BC cells. Noteworthy, our findings suggest that EphA3 may be considered as a novel RAGE target gene facilitating BC invasion and scattering from the primary tumor mass. Overall, the current results may provide useful insights for more comprehensive therapeutic approaches in BC, particularly in obese and diabetic patients that are characterized by high RAGE levels.
    Journal
    |
    ER (Estrogen receptor) • EPHA3 (EPH receptor A3)
    |
    ER positive
    over1year
    Circular RNA EPHA3 suppresses progression and metastasis in prostate cancer through the miR-513a-3p/BMP2 axis. (PubMed, J Transl Med)
    As a tumor suppressor, circEPHA3 inhibited the proliferation and metastasis of PCa cells through the miR-513a-3p/BMP2 axis, suggesting that circEPHA3 might be a potential therapeutic target for PCa.
    Journal
    |
    EPHA3 (EPH receptor A3) • MIR513A1 (MicroRNA 513a-1)
    |
    dactinomycin
    over1year
    Knockdown of circ_CLIP2 regulates the proliferation, metastasis and apoptosis of glioma cells through miR-641/EPHA3/STAT3 axis. (PubMed, J Neurogenet)
    In addition, EPHA3 overexpression could abolish the inhibitory effects of miR-641 overexpression on the malignant behaviors of glioma cells by activating the signal transducer and activator of transcription 3 (STAT3). These findings elucidated that circ_CLIP2 knockdown suppressed glioma development by regulation of the miR-641/EP HA3/STAT3 axis, which provided a novel mechanism for understanding the pathogenesis of glioma.
    Journal
    |
    EPHA3 (EPH receptor A3)
    over1year
    EphA3 deficiency in the hypothalamus promotes high-fat diet-induced obesity in mice. (PubMed, J Biomed Res)
    Knockdown of EphA3 leads to smaller intracellular vesicles in GT1-7 cells. The current study reveals that hypothalamic EphA3 plays important roles in promoting DIO.
    Preclinical • Journal
    |
    EPHA3 (EPH receptor A3)
    over1year
    A large-scale screening and functional sorting of tumour microenvironment prognostic genes for breast cancer patients. (PubMed, Front Endocrinol (Lausanne))
    The external relationships between these TME prognostic genes and the disease were measured. Meanwhile, the internal molecular mechanisms were also investigated.
    Journal
    |
    EPHA3 (EPH receptor A3) • IRF1 (Interferon Regulatory Factor 1) • MEN1 (Menin 1) • NOS2 (Nitric Oxide Synthase 2) • PDLIM4 (PDZ and LIM domain 4)
    |
    IRF1 expression
    almost2years
    Simultaneous targeting of EphA3 on glioblastoma and tumor microenvironment to overcome resistance to CART cell therapy in brain cancer (AACR 2023)
    MSC conditioned coculture of GBM and CART showed significant suppression of CAR19 in the CART19 - JeKo-1 system (p=000.3), but no significant suppression of EphA3-CART cells. In summary, our results indicate that EphA3 CART cells exhibited potent and specific antitumor activity in vitro and in vivo and ameliorated MSC induced inhibition of CART cell functions, representing a potentially promising therapeutic option in GBM.
    CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • EPHA3 (EPH receptor A3)
    almost2years
    EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer. (PubMed, Cancers (Basel))
    EPHA3 could be regarded as an acceptable anti-cancer biomarker in BLCA. EPHA3 plays an inhibiting role in BLCA, and it could be the candidate immunotherapeutic target for BLCA.
    Journal • IO biomarker
    |
    EPHA3 (EPH receptor A3)
    almost2years
    Chromosomal Aberrations Accumulate During Metastasis of Virus-negative Merkel Cell Carcinoma. (PubMed, J Invest Dermatol)
    VN-MCCs have complex combinations of somatic DNA sequence variants and CNVs. They likely carry the small genomic changes permissive for metastasis from early tumor development; however, chromosomal alterations may contribute to driving metastatic progression.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • LRP1B (LDL Receptor Related Protein 1B) • EPHA3 (EPH receptor A3)
    almost2years
    Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition. (PubMed, PLoS Pathog)
    RNF5 inhibition decreased PEL xenograft tumor growth and downregulated viral gene expression, cell cycle gene expression, and hedgehog signaling in xenograft tumors. Our study suggests that RNF5 plays the critical roles in KSHV lytic infection and tumorigenesis of primary effusion lymphoma.
    Journal
    |
    EPHA3 (EPH receptor A3) • EPHA4 (EPH Receptor A4)
    almost2years
    Inhibiting stromal fibrosis in pancreatic cancer (LCC 2023)
    To investigate whether EphA3 expression in the PDAC TME supports tumour growth, we generated transgenic mice with doxycycline (Dox) inducible shRNA- mediated knockdown of EphA3 expression...Our results indicate that in vivo knockdown of EphA3 results in reduced tumour growth in mice, indicating an important role of CAFs/MSCs recruited to tumours. Targeting EphA3 on cells, such as with antibody-based drugs, could be a therapeutic approach to inhibit pancreatic tumour growth.
    Stroma
    |
    EPHA3 (EPH receptor A3)
    almost2years
    May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment? (PubMed, Int J Mol Sci)
    Collectively, EPHs/ephrins seem to represent promising treatment targets in LC. However, large clinical trials still need to be performed, with a view to examining the effects of EPH/ephrin targeting in the clinical setting.
    Review • Journal
    |
    EPHA3 (EPH receptor A3) • EPHB4 (EPH receptor B4) • EPHA5 (EPH Receptor A5) • EPHA7 (EPH Receptor A7) • EFNA1 (Ephrin A1)
    almost2years
    EphA3 targeted by miR-3666 contributes to melanoma malignancy via activating ERK1/2 and p38 MAPK pathways. (PubMed, Open Med (Wars))
    In conclusion, miR-3666 downregulated EphA3 expression and retarded melanoma malignancy via inactivating ERK1/2 and p38 MAPK pathways. Hence, miR-3666/EphA3 axis may represent a druggable target against melanoma progression.
    Journal
    |
    EPHA3 (EPH receptor A3)
    2years
    A novel prognostic model based on cellular senescence-related gene signature for bladder cancer. (PubMed, Front Oncol)
    In addition, risk score were positively correlated with multiple immunotherapy biomarkers. Our study revealed that a novel model based on senescence-related genes could serve as a reliable predictor of survival for patients with BCa.
    Journal • Gene Signature • IO biomarker
    |
    TGFB1I1 (Transforming growth factor beta 1 induced transcript 1) • EPHA3 (EPH receptor A3) • TGFB1 (Transforming Growth Factor Beta 1)
    2years
    In Silico Binding Analysis of Cannabinoids with Eph Receptors for Therapeutic Use in Gliomas. (PubMed, MedPress Psychiatry Behav Sci)
    Further analysis revealed that these cannabinoids bind to specific locations on Eph receptors required for Eph/ephrin interactions. The findings suggest that certain cannabinoids can effectively bind to hydrophobic pockets required for ephrin binding and thereby be used to block subsequent Eph/ephrin interactions.
    Journal
    |
    EPHA3 (EPH receptor A3) • EPHB2 (EPH Receptor B2) • EPHB4 (EPH receptor B4) • EPHB3 (EPH Receptor B3)
    2years
    Progressive abdominal pain with acute exacerbation due to retroperitoneal follicular dendritic cell sarcoma: a case report with targeted genomic sequencing analysis. (PubMed, Acta Chir Belg)
    The interpretations of CA724, PET/CT, as well as imaging results deserve further investigation in FDCS. Genomic sequencing revealed three novel gene mutations in FDCS, including EPHA3 (nonsense mutation), DDR2 (SNV), and BIRC3 (InDel).
    Journal
    |
    BIRC3 (Baculoviral IAP repeat containing 3) • EPHA3 (EPH receptor A3) • DDR2 (Discoidin domain receptor 2)
    |
    EPHA3 mutation
    2years
    Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. (PubMed, Prostate Cancer)
    HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.
    P2 data • Journal
    |
    EPHA3 (EPH receptor A3)
    |
    Erleada (apalutamide)
    2years
    Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma. (PubMed, Cells)
    Additionally, we identified potential subtype-specific therapeutic targets, including CCNE1, EPHA3, RNF43, ROS1, and RSPO2 for subtype I and CDKN2A and RET for subtype II. Considering the need for potent diagnostic and therapeutic biomarkers for eMPM, we are anticipating that our findings will help both in exploring underlying mechanisms in the development of eMPM and in designing targeted therapy for eMPM.
    Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCNE1 (Cyclin E1) • RNF43 (Ring Finger Protein 43) • EPHA3 (EPH receptor A3) • RSPO2 (R-Spondin 2)
    2years
    Subtype Classification and Prognosis Signature Construction of Osteosarcoma Based on Cellular Senescence-Related Genes. (PubMed, J Oncol)
    Nomogram constructed by CSRS score and metastatic has a high prognostic value for OS. Our study identified a molecular classification determined by CS-related genes and developed a new CSRS that has potential value in OS immunotherapy response and clinical outcome prediction.
    Journal • IO biomarker
    |
    EPHA3 (EPH receptor A3)
    over2years
    Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. (PubMed, Front Pharmacol)
    In vivo studies showed that the median survival time of tumor-bearing nude mice in the anti-EphA3-TMZ16e-NPs group was extended to 41 days, which was 1.71-fold higher than that of the saline group and the TUNEL staining results of the brain tissue section indicated that the TMZ16e-loaded NPs could elevate apoptosis in T98G cells. In conclusion, the TMZ16e-loaded NPs can be effectively delivered to the brain and targeted to gliomas, exhibiting better anti-glioma activity, indicating they possess great potential in the treatment of drug-resistant glioma.
    Journal
    |
    EPHA3 (EPH receptor A3)
    |
    temozolomide
    over2years
    Novel neoplasms associated with syndromic pediatric medulloblastoma: integrated pathway delineation for personalized therapy. (PubMed, Cell Commun Signal)
    This study presents the spatiotemporal evolution of novel neoplastic associations in syndromic medulloblastoma, and discusses the post-radiotherapy risk for secondary malignancies in syndromic pediatric patients, with important implications for the biology, diagnosis, and therapy of these tumors. Video Abstract.
    Journal • PARP Biomarker
    |
    ALK (Anaplastic lymphoma kinase) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • EPHA3 (EPH receptor A3) • TGFB1 (Transforming Growth Factor Beta 1) • PRLR (Prolactin Receptor 2) • XRCC3 (X-Ray Repair Cross Complementing 3)
    |
    FAP overexpression
    over2years
    Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. (PubMed, Clin J Gastroenterol)
    Although he received chemotherapy with the combination of gemcitabine and cisplatin, he had renal failure and discontinued the chemotherapy...Molecular carcinogenesis of IHMC may be distinct from that of ordinary cholangiocarcinoma. Further studies are needed to elucidate the genetic mutations and their functions in IHMC.
    Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • EPHA3 (EPH receptor A3) • PIK3C2B (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • ADGRB3 (Adhesion G Protein-Coupled Receptor B3) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)
    |
    BRIP1 mutation
    |
    cisplatin • gemcitabine • Teysuno (gimeracil/oteracil/tegafur)
    over2years
    Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy (IASLC-WCLC 2022)
    Preliminary data seem to support the idea of ​​the existence of different profiles depending on the metastatic site. However, the small sample size means that further studies are required to validate these data.
    Clinical • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • NF1 (Neurofibromin 1) • KMT2D (Lysine Methyltransferase 2D) • FLT1 (Fms-related tyrosine kinase 1) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • SOX2 • EPHA3 (EPH receptor A3) • KLHL6 (Kelch Like Family Member 6)
    |
    TP53 mutation • KRAS mutation • BRCA1 mutation • EGFR mutation • ATM mutation • NF1 mutation • KMT2D mutation • APC mutation • MLL2 mutation
    |
    Guardant360® CDx
    over2years
    Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors. (PubMed, Front Genet)
    These genes were analyzed by RT-PCR, and it was confirmed that the expression trend of FABP4, COL4A1, and RGS4 in different imatinib-resistant cell lines was in accord with the GEO database. It is suggested that these genes may play a potential role in the clinical diagnosis and treatment of imatinib resistance in GIST.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • EPHA3 (EPH receptor A3) • FABP4 (Fatty Acid Binding Protein 4)
    |
    imatinib
    over2years
    Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo. (PubMed, Antioxidants (Basel))
    Indolium 1 has a novel mechanism of action against melanoma, in that it results in induction of the tumor-suppressor EPHA3. We believe that pre-IND studies are warranted for this novel compound, given its mechanism of action and ability to inhibit the growth of vemurafenib resistant melanoma in vivo.
    Preclinical • Journal • IO biomarker
    |
    EPHA3 (EPH receptor A3)
    |
    BRAF mutation
    |
    Zelboraf (vemurafenib)
    over2years
    Genomic features of Chinese small cell lung cancer. (PubMed, BMC Med Genomics)
    Our data might provide an insightful meaning in targeted therapy for Chinese SCLC patients.
    Journal • Tumor Mutational Burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • MSH2 (MutS Homolog 2) • CREBBP (CREB binding protein) • TSC1 (TSC complex subunit 1) • NOTCH3 (Notch Receptor 3) • FOXA1 (Forkhead Box A1) • EPHA3 (EPH receptor A3) • ATXN3 (Ataxin 3)
    |
    TP53 mutation • EGFR mutation • TMB-H
    over2years
    ADAM10-cleaved ephrin-A5 contributes to prostate cancer metastasis. (PubMed, Cell Death Dis)
    The receiver operating characteristic curve(ROC) showed that the area under the curve(AUC) of serum ephrin-A5 as a marker of PCa metastasis was 0.843, with a sensitivity of 93.5% and a specificity of 75%. It is concluded that ADAM10-mediated ephrin-A5 shedding promotes PCa metastasis via transforming the role of EphA3 from ligand-dependent tumor suppressor to ligand-independent promoter, and ephrin-A5 in the blood can be used as a new biomarker for PCa metastasis.
    Journal
    |
    EPHA3 (EPH receptor A3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ADAM10 (ADAM Metallopeptidase Domain 10) • EFNA5 (Ephrin A5)
    |
    CD31 expression
    over2years
    Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. (PubMed, Mol Pharm)
    In vivo thermal imaging results showed that GNPs could enter the brain via intranasal administration and be eliminated in 2 days, indicating that GNPs are safe for brain. In conclusion, GNPs-PPTT could effectively induce apoptosis in glioma cells and reverse TMZ resistance, thereby, indicative of a promising treatment strategy for GBM.
    Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • EPHA3 (EPH receptor A3)
    |
    temozolomide
    over2years
    CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer. (PubMed, Front Oncol)
    In the validation cohort, CAF-associated signaling is also associated with therapy failure in general EOC, possibly hinting towards a conserved mechanism. Therefore, it may be helpful to stratify HGSOC patients for CAF activity and consider alternative treatment options.
    Journal
    |
    EPHA3 (EPH receptor A3) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • TGFB1 (Transforming Growth Factor Beta 1)
    almost3years
    Genomic characteristics of classic and uncommon EGFR activating mutations explains different responses to first-generation EGFR-TKIs (AACR 2022)
    This comprehensive analysis of EGFR-positive mutational landscape revealed specific genomic characteristics associated with uncommon EGFR mutations that might explain their poor response to first-generation TKIs.
    Tumor Mutational Burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • GATA6 (GATA Binding Protein 6) • EPHA3 (EPH receptor A3)
    |
    TP53 mutation • EGFR mutation • TMB-H • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive • EGFR G719X + EGFR S768I
    almost3years
    Artesunate-induced Cellular Effects Are Mediated by Specific EPH Receptors and Ephrin Ligands in Breast Carcinoma Cells. (PubMed, Cancer Genomics Proteomics)
    The relative changes in artesunate-treated MCF7 and MDA-MB-231 cells as compared to similarly treated MCF10A cells allow us to implicate combinatorial expression and receptor interactions for EPH receptor-mediated signal transduction that converges into pathways responsible for cell growth, proliferation, and apoptosis. Specifically, the alterations in EPHA7, EPHA8, EPHA10 and EPHB6 transcripts appear to be important participants in artesunate-mediated cellular effects.
    Journal
    |
    EPHA3 (EPH receptor A3) • EPHA7 (EPH Receptor A7)
    almost3years
    Emodin Protects SH-SY5Y Cells Against Zinc-Induced Synaptic Impairment and Oxidative Stress Through the ERK1/2 Pathway. (PubMed, Front Pharmacol)
    Moreover, emodin inhibited the generation of reactive oxygen species and oxidative stress and facilitated the collapse of mitochondrial membrane potential (ΔΨm) in SH-SY5Y cells. In conclusion, our results indicated that emodin exerts neuroprotective effects against zinc by normalizing synaptic impairment by decreasing the phosphorylation of ERK1/2, reducing reactive oxygen species and protecting mitochondrial function.
    Journal
    |
    SYP (Synaptophysin)
    almost3years
    International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma. (PubMed, Front Immunol)
    The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. The IPI-IPM has independent prognostic significance for DLBCL patients, which provides an immunological perspective to elucidate the mechanisms of tumor progression and sheds light on the development of immunotherapy for DLBCL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • EPHA3 (EPH receptor A3) • BTLA (B And T Lymphocyte Associated)
    |
    KMT2D mutation • CD79B mutation • CD79B mutation